ITEM 2.02 Results of Operations and Financial Condition

On February 7, 2020, Myriad Genetics, Inc. ("Myriad") posted a corrected press release on its website announcing its financial results for the three and six months ended December 31, 2019 to correct the earnings release issued on February 6, 2020 ("Original Release"). The Original Release inadvertently stated in the Reconciliation of GAAP to Non-GAAP Financial Measures that GAAP earnings per share was $(0.38) for the six months ended December 31, 2019. The correct GAAP earnings per share was $(0.39) for the six months ended December 31, 2019. The Original Release also inadvertently used incorrect inputs in the Free Cash Flow Reconciliation for the three months ended December 31, 2019 and December 31, 2018 and inadvertently omitted the settlement of the hereditary cancer qui tam complaint in the calculation of non-GAAP free cash flow for the three and six months ended December 31, 2019. Myriad has prepared and furnished, as Exhibit 99.1 to this Amendment, a corrected earnings release which includes the corrected information. The corrections to the Reconciliation of GAAP to Non-GAAP Financial Measures and the Free Cash Flow Reconciliation did not impact Myriad's GAAP results reported in the Original Release and did not change Myriad's guidance that it provided in the Original Release. The corrected earnings release is attached hereto as Exhibit 99.1 to this Amendment and incorporated herein by reference.

ITEM 7.01 Regulation FD Disclosure

On its earnings conference call for the three and six months ended December 31, 2019, Myriad also delivered a slide presentation, which is attached hereto as Exhibit 99.2 to this Current Report on Form 8-K and incorporated herein by reference. The slide presentation will also be available under the "Investors -Events & Presentations" section of Myriad's website at www.myriad.com.



                           FORWARD-LOOKING STATEMENTS

Exhibits 99.1 and 99.2 contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to our business, goals, strategy and financial and operational outlook. These "forward-looking statements" are management's present expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by forward-looking statements. These risks include, but are not limited to: the risk that sales and profit margins of our existing molecular diagnostic tests and pharmaceutical and clinical services may decline or will not continue to increase at historical rates; risks related to our ability to transition from our existing product portfolio to our new tests; risks related to changes in the governmental or private insurers reimbursement levels for our tests or our ability to obtain reimbursement for our new tests at comparable levels to our existing tests; risks related to increased competition and the development of new competing tests and services; the risk that we may be unable to develop or achieve commercial success for additional molecular diagnostic tests and pharmaceutical and clinical services in a timely manner, or at all; the risk that we may not successfully develop new markets for our molecular diagnostic tests and pharmaceutical and clinical services, including our ability to successfully generate revenue outside the United States; the risk that licenses to the technology underlying our molecular diagnostic tests and pharmaceutical and clinical services tests and any future tests are terminated or cannot be maintained on satisfactory terms; risks related to delays or other problems with operating our laboratory testing facilities; risks related to public concern over our genetic testing in general or our tests in particular; risks related to regulatory requirements or enforcement in the United States and foreign countries and changes in the structure of the healthcare system or healthcare payment systems; risks related to our ability to obtain new corporate collaborations or licenses and acquire new technologies or businesses on satisfactory terms, if at all; risks related to

--------------------------------------------------------------------------------

our ability to successfully integrate and derive benefits from any technologies or businesses that we license or acquire; risks related to our projections about the potential market opportunity for our products; the risk that we or our licensors may be unable to protect or that third parties will infringe the proprietary technologies underlying our tests; the risk of patent-infringement claims or challenges to the validity of our patents; risks related to changes in intellectual property laws covering our molecular diagnostic tests and pharmaceutical and clinical services and patents or enforcement in the United States and foreign countries, such as the Supreme Court decisions in Mayo Collab. Servs. v. Prometheus Labs., Inc., 566 U.S. 66 (2012), Ass'n for Molecular Pathology v. Myriad Genetics, Inc., 569 U.S. 576 (2013), and Alice Corp. v. CLS Bank Int'l, 573 U.S. 208 (2014); risks of new, changing and competitive technologies and regulations in the United States and internationally; the risk that we may be unable to comply with financial operating covenants under our credit or lending agreements; the risk that we will be unable to pay, when due, amounts due under our credit or lending agreements; and other factors discussed under the heading "Risk Factors" contained in Item 1A of our most recent Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as well as any updates to those risk factors filed from time to time in our Quarterly Reports on Form 10-Q or Current Reports on Form 8-K. All information in the exhibits is as of the date of the exhibits, and Myriad undertakes no duty to update this information unless required by law.

--------------------------------------------------------------------------------

ITEM 9.01 Financial Statements and Exhibits.






Exhibit
Number    Description

99.1        Earnings release dated February 6, 2020 for the three and six months
          ended December 31, 2019, as corrected on February 7, 2020.

99.2*       Earnings call slide presentation dated February 6, 2020 for the three
          and six months ended December 31, 2019.

104       Cover Page Interactive Data File (embedded within the Inline XBRL
          document).




*Previously filed.

The exhibit(s) may contain hypertext links to information on our website or other parties' websites. The information on our website and other parties' websites is not incorporated by reference into this Current Report on Form 8-K and does not constitute a part of this Form 8-K.

In accordance with General Instruction B-2 of Form 8-K, the information set forth in Item 2.02 and Item 7.01 and in Exhibits 99.1 and 99.2 shall not be deemed to be "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that section, and shall not be incorporated by reference into any registration statement or other document filed under the Securities Act of 1933, as amended or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses